Relief of Neuropathic Pain After Spinal Cord Stimulator Implantation in a Patient With Idiopathic Thoracic Transverse Myelitis: A Case Report.
Clicks: 314
ID: 16762
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
77.2
/100
314 views
231 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #2 of 3 articles by views in a&a practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Transverse myelitis (TM) is a rare neurologic disorder of acute inflammation resulting in spinal cord injury. Chronic pain in TM is a significant detriment to quality of life. Spinal cord stimulation (SCS) is an emerging treatment that has shown significant efficacy in neuropathic pain. We present a 37-year-old man with a history of idiopathic thoracic TM and refractory chronic neuropathic pain who underwent an SCS trial. He reported 70% improvement during the trial and was subsequently implanted with an SCS. He continues to experience significant pain relief and functional improvement (>80%) with conventional paresthesia programming at the 9-month follow-up.
| Reference Key |
reddy2019reliefaa
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Reddy, Rajiv;Prasad, Rupa;Rejai, Sepehr;Halter, Kenneth;Chen, Jeffrey; |
| Journal | a&a practice |
| Year | 2019 |
| DOI |
10.1213/XAA.0000000000001078
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.